Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesSatraplatin: leading the new generation of oral platinum agents
Expert Opinion on Investigational Drugs, 11/06/09
Bhargava A et al. – Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. The oral route of administration and the intermittent schedule makes it very convenient for clinical use. Despite this, a FDA–approved indication has not yet been achieved. The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate–resistant prostate cancer (CRPC), revealing an improvement in progression–free survival but no overall survival benefit. Future development would have to include designing trials in docetaxel–refractory metastatic CRPC, or in other malignancies where cisplatin is of benefit.
Related Articles
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The Sparc trial
Journal of Clinical Oncology, 10/08/09
Relevance Score: 94%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Chronic Obstructive Pulmonary Disease: Role of Bacteria and Updated Guide to Antibacterial Selection in the Older Patient
Drugs & Aging, 11/25/09
Using Marginal Structural Measurement-Error Models to Estimate the Long-term Effect of Antiretroviral Therapy on Incident AIDS or Death
American Journal of Epidemiology, 11/25/09
Emergency Influenza Drug
JAMA, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor